CAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied.
Leerink Partners is lead placement agent for the $50 million upfront, with Piper Sandler & Co., Cantor Fitzgerald and Wedbush & Co. as co-placement agents. The second $50 million depends on milestones, including clearance to start a trial of CMP-SYNGAP-01.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $86.4 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about CAMP4 Therapeutics
Has CAMP4 Therapeutics raised money recently?
Our latest story on this, dated Aug 4, 2026: "CAMP4 completes second closing of private placement for $50.1 million gross proceeds". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of CAMP4 Therapeutics?
CAMP4 Therapeutics Corporation trades under the ticker CAMP on NASDAQ.
Where is CAMP4 Therapeutics listed?
CAMP4 Therapeutics Corporation is listed on NASDAQ.
What is the SEC CIK of CAMP4 Therapeutics?
The SEC Central Index Key (CIK) for CAMP4 Therapeutics Corporation is 1736730. Its filings are on SEC EDGAR.
How many shares does CAMP4 Therapeutics have outstanding?
62,753,200 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is CAMP4 Therapeutics listed under?
Our directory records CAMP4 Therapeutics Corporation under United States.
What does CAMP4 Therapeutics do?
Our directory classifies CAMP4 Therapeutics Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of CAMP4 Therapeutics?
The ISIN recorded for CAMP4 Therapeutics Corporation is US13463J1016.
Does aibio.space cover CAMP4 Therapeutics?
aibio.space lists CAMP4 Therapeutics Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
Where is CAMP4 Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was CAMP4 Therapeutics's revenue last year?
$3.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is CAMP4 Therapeutics profitable?
CAMP4 Therapeutics Corporation reported a net loss of $80.4 million for the fiscal year ended Dec 31, 2025, and used $29.6 million of cash in operations, per its annual report to the SEC.
How much does CAMP4 Therapeutics spend on research and development?
$38.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does CAMP4 Therapeutics have?
$86.4 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest CAMP4 Therapeutics (CAMP) stock news?
Our latest story on CAMP4 Therapeutics, dated Aug 4, 2026: "CAMP4 completes second closing of private placement for $50.1 million gross proceeds". CAMP4 Therapeutics sold 10,756,498 shares and pre-funded warrants for 21,925,368 shares on August 3, 2026, after the trigger for the second closing was satisfied. Source.
Investor discussion: CAMP4 Therapeutics
Members talk about CAMP4 Therapeutics (CAMP). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at CAMP4 Therapeutics, newest first. Each line links the filing it comes from.
Financings
Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CAMP on TradingView.
SEC filings and registration
SEC name
Camp4 Therapeutics Corp
CIK
1736730
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CAMP (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
100 TALCOTT AVENUE, WATERTOWN, MA, 02472
Phone
617-651-8867
Shares outstanding
62,753,200 as of 2026-08-12 (10-Q filed 2026-08-13)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
CAMP4 Therapeutics Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CAMP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio